Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma

Phase I study of the irreversible FGFR1 ‐4 inhibitor futibatinib in Japanese patients with advanced solid tumors

(2022) Toshihiko Doi et al.   CANCER SCIENCE

The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer

(2022) J.E. Berchuck et al.   ANNALS OF ONCOLOGY

Clinicopathological characteristics and prognostic factors for intrahepatic cholangiocarcinoma: a population-based study

(2021) Tian-hua Yu et al.   Scientific Reports

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

(2021) Angela Lamarca et al.   LANCET ONCOLOGY

FGFR2 Extracellular Domain In-Frame Deletions are Therapeutically Targetable Genomic Alterations that Function as Oncogenic Drivers in Cholangiocarcinoma

(2021) James M. Cleary et al.   Cancer Discovery

Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study

(2021) Funda Meric-Bernstam et al.   Cancer Discovery

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

(2021) Milind Javle et al.   Lancet Gastroenterology & Hepatology

Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma

(2020) Melanie A. Krook et al.   MOLECULAR CANCER THERAPEUTICS

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

(2020) Ghassan K Abou-Alfa et al.   LANCET ONCOLOGY

Phase 1, First-in-Human Study of Futibatinib, a Highly Selective, Irreversible FGFR1–4 Inhibitor in Patients with Advanced Solid Tumors

(2020) R. Bahleda et al.   ANNALS OF ONCOLOGY

Cholangiocarcinoma 2020: the next horizon in mechanisms and management

(2020) Jesus M. Banales et al.   Nature Reviews Gastroenterology & Hepatology

Futibatinib is a novel irreversible FGFR 1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors

(2020) Hiroshi Sootome et al.   CANCER RESEARCH

Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers

(2020) Angela Lamarca et al.   Journal of Clinical Medicine

Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib

(2020) Ian M. Silverman et al.   Cancer Discovery

TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure

(2019) Maria Kalyukina et al.   ChemMedChem

Combination versus mono-therapy as second-line treatment for advanced biliary tract cancer: a systematic review and meta-analysis of published data

(2019) Jie Ying et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Recurrence Patterns and Timing Courses Following Curative-Intent Resection for Intrahepatic Cholangiocarcinoma

(2019) Liang-Shuo Hu et al.   ANNALS OF SURGICAL ONCOLOGY

TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma

(2019) Lipika Goyal et al.   Cancer Discovery

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

(2019) Suresh S. Ramalingam et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

(2018) Milind Javle et al.   JOURNAL OF CLINICAL ONCOLOGY

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

(2018) Vincenzo Mazzaferro et al.   BRITISH JOURNAL OF CANCER

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

(2017) Solange Peters et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

(2017) Nader N. Massarweh et al.   Cancer Control

Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH -Mutant Molecular Profiles

(2017) Farshad Farshidfar et al.   Cell Reports

Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise

(2016) Supriya K. Saha et al.   ONCOLOGIST

Polyclonal SecondaryFGFR2Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma

(2016) Lipika Goyal et al.   Cancer Discovery

Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations

(2015) Leandro H. Gallo et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data

(2015) Lorenzo Fornaro et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

(2015) Pasi A. Jänne et al.   NEW ENGLAND JOURNAL OF MEDICINE

Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma

(2015) Daniela Sia et al.   Nature Communications

The N550K/H Mutations in FGFR2 Confer Differential Resistance to PD173074, Dovitinib, and Ponatinib ATP-Competitive Inhibitors

(2015) Sara A Byron et al.   NEOPLASIA

Second-line chemotherapy in advanced biliary cancer: a systematic review

(2014) A. Lamarca et al.   ANNALS OF ONCOLOGY

Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma

(2014) Rondell P. Graham et al.   HUMAN PATHOLOGY

Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma

(2013) Yasuhito Arai et al.   HEPATOLOGY

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER